AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 21461792
Drug: Dexmedetomidine (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine (2 μg·kg(‐1) and 4 μg·kg(‐1) combined)
Trial: 21461792
Drug: Dexmedetomidine (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine (2 μg·kg(‐1))
Trial: 21461792
Drug: Fentanyl (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fentanyl (1 μg·kg(‐1))
Trial: 19125241
Drug: 150 mg
RxNorm normalized name: pectin 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg idebenone
Trial: 19125241
Drug: 750 mg
RxNorm normalized name: bran 750 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 750 mg idebenone
Trial: 19125241
Drug: idebenone (up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: idebenone (up to 2,250 mg/day)
Trial: 11707794
Drug: Epidural bupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural bupivacaine 0.25%, 12 mL
Trial: 30544518
Drug: DHA supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DHA supplementation (0 to 7 mg/kg/day for six months)
Trial: 24397061
Drug: Local steroid
RxNorm normalized name: RECTAL,LOCAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local steroid injection (triamcinolone 20 mg mixed with lignocaine 2% 1 cc) and topical NSAID cream (diclofenac diethylammonium) twice a day, tab. diclofenac sodium 50 mg twice a day for 3 weeks
Trial: 24397061
Drug: Tab diclofenac
RxNorm normalized name: diclofenac Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tab diclofenac 50 mg twice a day and topical NSAID cream application twice a day for 3 weeks
Trial: 18706164
Drug: OROS‐MPH (18
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OROS‐MPH (18 mg/time, once daily)
Trial: 18706164
Drug: IR‐MPH (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IR‐MPH (5 mg/time, twice or three times per day)
Trial: 15482357
Drug: Effervescent ASA
RxNorm normalized name: aspirin Effervescent Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Effervescent ASA (1000 mg)
Trial: 16109110
Drug: Sumatriptan (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sumatriptan (50 mg)
Trial: 11182878
Drug: PAS intervention
RxNorm normalized name: PAS
DrugBank: Aminosalicylic acid (DB00233)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: PAS intervention (structured counselling programme, information leaflet, follow-up weekly for the first 4 weeks then monthly as needed)
Trial: 9608351
Drug: Methylphenidate (MPH)
DrugBank: Methylphenidate (DB00422)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methylphenidate (MPH) 25 mg per day
Trial: 9608351
Drug: Methylphenidate (MPH)
DrugBank: Methylphenidate (DB00422)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methylphenidate (MPH) 50 mg per day
Trial: 9608351
Drug: Methylphenidate (MPH)
DrugBank: Methylphenidate (DB00422)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methylphenidate (MPH) 75 mg per day
Trial: 7995316
Drug: Scopolamine-TTS (1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Scopolamine-TTS (1.5 mg)
Trial: 21113636
Drug: Caudal epidural
RxNorm normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caudal epidural injection with 20 ml volume (5 ml contrast, 2 ml Triamcinolone, 13 ml local anaesthetic)
Trial: 18290733
Drug: Ropivacaine (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ropivacaine (5 injections of 2 mL 0.5% ropivacaine around the ureteral orifice)
Trial: 18290733
Drug: Control (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (5 injections of 2 mL of 0.9% normal saline)
Trial: 12589284
Drug: Injection molded
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection molded and microwave polymerized (Microbase)
Trial: 12589284
Drug: Injection molded
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection molded and microwave polymerized (Acron MC)
Trial: 12589284
Drug: Injection molded
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection molded and conventionally polymerized (Success)
Trial: 11238495
Drug: MK-677 (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MK-677 (25 mg)
Trial: 8449202
Drug: Intravenous magnesium
RxNorm normalized name: immunoglobulins, intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous magnesium sulphate (70 mmol)
Trial: 24275677
Drug: Alendronate 70mg
RxNorm normalized name: ALENDRONATE 70MG TAB
DrugBank: Alendronic acid (DB00630)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Alendronate 70mg weekly
Trial: 22143734
Drug: 2% NaF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2% NaF solution
Trial: 22143734
Drug: GLUMA® (HEMA-G)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GLUMA® (HEMA-G)
Trial: 7871004
Drug: ondansetron (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ondansetron (4 mg orally)
Trial: 3096345
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no antibiotic prophylaxis) for wounds >1 cm requiring suturing
Trial: 24162387
Drug: 5-fluorouracil continuous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5-fluorouracil continuous infusion (5-FUci)
Trial: 24162387
Drug: Second-line chemotherapy
RxNorm normalized name: Gallus gallus gizzard lining preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Second-line chemotherapy with new drugs
Trial: 10436948
Drug: Cefetamet pivoxil
RxNorm normalized name: Cefetamet pivoxil
DrugBank: Cefetamet pivoxil (DB18915)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefetamet pivoxil (CAT) 250‐500 mg, twice daily orally for 7‐10 days
Trial: 10436948
Drug: Cefixime (CFX)
RxNorm normalized name: Cefixime
DrugBank: Cefixime (DB00671)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cefixime (CFX) 200 mg, twice daily orally for 7‐10 days
Trial: 8248693
Drug: Intracervical Foley
RxNorm normalized name: eladocagene exuparvovec
DrugBank: Eladocagene exuparvovec (DB16780)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intracervical Foley catheter with balloon inflated to 50 cc
Trial: 8248693
Drug: Extraamniotic injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extraamniotic injection of prostaglandins E2 via a Foley catheter with balloon inflated to 50 cc
Trial: 3516907
Drug: 3% benzydamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3% benzydamine cream
Trial: 31282567
Drug: Intravenous pantoprazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous pantoprazole 40 mg once daily during ICU stay
Trial: 31282567
Drug: Placebo (saline)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (saline) once daily during ICU stay
Trial: 23930551
Drug: GAKIC (10.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GAKIC (10.2 g)
Trial: 16489434
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg baclofen (BAC)
Trial: 14689713
Drug: TN therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TN therapy
Trial: 8824690
Drug: Dichloroacetate (DCA)
RxNorm normalized name: dichloroacetate
DrugBank: Sodium dichloroacetate (DB16929)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dichloroacetate (DCA) 46 mg kg-1 infused in 30 min
Trial: 8824690
Drug: Dichloroacetate (DCA)
RxNorm normalized name: dichloroacetate
DrugBank: Sodium dichloroacetate (DB16929)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dichloroacetate (DCA) 46 mg kg-1 infused in 30 min (2 doses)
Trial: 1314144
Drug: ICI 169,369
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ICI 169,369 (30 mg x 2)
Trial: 1314144
Drug: ICI 169,369
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ICI 169,369 (80 mg x 2)
Trial: 30777118
Drug: 100,000 IU
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100,000 IU vitamin D3 (two oral doses, once in the fall and once in the winter)
Trial: 27389681
Drug: PA21 (sucroferric
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PA21 (sucroferric oxyhydroxide) 250 mg, 500 mg, 750 mg, or 1000 mg three times/day for 6 weeks
Trial: 24742292
Drug: 5HT antagonist
RxNorm normalized name: Interleukin-1 receptor antagonist anakinra
DrugBank: Anakinra (DB00026)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 5HT antagonist
Trial: 19707983
Drug: Enalapril 20
RxNorm normalized name: enalapril 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril 20 mg/d for 6 days
Trial: 18027401
Drug: 0.4% stannous
RxNorm normalized name: Stanimax 0.4% Stannous Fluoride Dental Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.4% stannous fluoride gel (control group)
Trial: 20627920
Drug: Albuterol (180
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Albuterol (180 microg)
Trial: 10540090
Drug: Suxamethonium 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Suxamethonium 1 mg x kg‐1
Trial: 2663585
Drug: Ibopamine 100
RxNorm normalized name: ibopamine 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibopamine 100 mg t.i.d.
Trial: 394144
Drug: Acebutolol (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acebutolol (400 mg per day for three days)
Trial: 31200893
Drug: Intramuscular trivalent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular trivalent inactivated influenza vaccine (IIV3)
Trial: 24784420
Drug: Adjuvant radiation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant radiation therapy (ART) recommendations without GC test result knowledge
Trial: 24784420
Drug: Treatment intensity
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment intensity
Trial: 23567146
Drug: Trastuzumab, lapatinib,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trastuzumab, lapatinib, or their combination with paclitaxel before surgery
Trial: 20047724
Drug: Standard cognitive-behavioral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard cognitive-behavioral therapy (CBT) for OCD
Trial: 20047724
Drug: Integrated cognitive-behavioral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Integrated cognitive-behavioral therapy (CBT) focusing on MDD in the first phase and OCD in the second phase
Trial: 17089228
Drug: 25 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg dexketoprofen
Trial: 15612853
Drug: Addiction treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Addiction treatments (specifics not provided)
Trial: 12861852
Drug: Acetaminophen (paracetamol)
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen (paracetamol)
Trial: 11567541
Drug: Coxibs (COX-2-specific
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Coxibs (COX-2-specific inhibitors)
Trial: 9258859
Drug: GHB 30
RxNorm normalized name: GHB
DrugBank: gamma-Hydroxybutyric acid (DB01440)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GHB 30 mg/kg
Trial: 8355645
Drug: Very early
RxNorm normalized name: Primula veris extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Very early treatment group (ET Gr)
Trial: 8355645
Drug: Postdischarge treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Postdischarge treatment group (PDT Gr)
Trial: 3300841
Drug: Potassium supplements
RxNorm normalized name: POTASSIUM SUPPLEMENTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Potassium supplements (48 mmol daily)
Trial: 3300841
Drug: Potassium supplements
RxNorm normalized name: POTASSIUM SUPPLEMENTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Potassium supplements (24 mmol daily) in a subgroup of 13 patients
Trial: 30089798
Drug: Ursodeoxycholic acid
RxNorm normalized name: Ursodeoxycholic acid
DrugBank: Ursodeoxycholic acid (DB01586)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ursodeoxycholic acid (UDCA) 300 mg twice daily for 8 weeks
Trial: 30089798
Drug: Vitamin E
RxNorm normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vitamin E 400 IU twice daily for 8 weeks
Trial: 17851535
Drug: Intranasal methamphetamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal methamphetamine 0 mg/70 kg
Trial: 17851535
Drug: Intranasal methamphetamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal methamphetamine 12 mg/70 kg
Trial: 17851535
Drug: Intranasal methamphetamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal methamphetamine 25 mg/70 kg
Trial: 17851535
Drug: Intranasal methamphetamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal methamphetamine 50 mg/70 kg
Trial: 15866571
Drug: P and
RxNorm normalized name: P and S
FDA approved: no
EMA approved: no
PMDA approved: no
Description: P and 2 mg of E2
Trial: 15866571
Drug: P and
RxNorm normalized name: P and S
FDA approved: no
EMA approved: no
PMDA approved: no
Description: P and 6 mg of E2
Trial: 12419088
Drug: Transdermal estrogen
RxNorm normalized name: estrogens
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal estrogen therapy (Climara, 50 microg 17beta‐estradiol for 3 months)
Trial: 7862384
Drug: 100-g GTT
RxNorm normalized name: petrolatum
DrugBank: Petrolatum (DB11058)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100-g GTT
Trial: 7862384
Drug: 50-g GTT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50-g GTT
Trial: 7862384
Drug: 75-g GTT
RxNorm normalized name: allantoin
DrugBank: Allantoin (DB11100)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 75-g GTT
Trial: 1936482
Drug: Bed-time NPH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bed-time NPH insulin (0.2 U/Kg)
Trial: 1936482
Drug: Metformin (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin (500 mg x 3)
Trial: 25265004
Drug: Early aqueous
RxNorm normalized name: ethylcellulose aqueous dispersion type A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Early aqueous suppression therapy (β‐blockers, α‐agonists, or carbonic anhydrase inhibitors) initiated when postoperative IOP >10 mm Hg (low‐IOP initiation group)
Trial: 25265004
Drug: Early aqueous
RxNorm normalized name: ethylcellulose aqueous dispersion type A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Early aqueous suppression therapy (β‐blockers, α‐agonists, or carbonic anhydrase inhibitors) initiated when postoperative IOP >17 mm Hg (moderate‐IOP initiation group)
Trial: 25265004
Drug: Early aqueous
RxNorm normalized name: ethylcellulose aqueous dispersion type A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Early aqueous suppression therapy (initiated before HP onset)
Trial: 25265004
Drug: Therapy initiated
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Therapy initiated after HP onset
Trial: 18773327
Drug: Inhaled budesonide
RxNorm normalized name: budesonide Inhalation Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled budesonide 200 mcg
Trial: 18773327
Drug: Inhaled fluticasone
RxNorm normalized name: fluticasone Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled fluticasone 125 mcg
Trial: 18773327
Drug: Inhaled budesonide
RxNorm normalized name: budesonide Inhalation Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled budesonide and fluticasone (both used on different occasions)
Trial: 18773327
Drug: 4-day treatment
RxNorm normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 4-day treatment protocol
Trial: 18773327
Drug: 8-day treatment
RxNorm normalized name: Otezla 10mg-20mg 28-Day Treatment Initiation Pack Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8-day treatment protocol
Trial: 18773327
Drug: 8-day treatment
RxNorm normalized name: Otezla 10mg-20mg 28-Day Treatment Initiation Pack Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8-day treatment protocol + azithromycin
Trial: 15742421
Drug: Killing Hp
RxNorm normalized name: HP 502
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Killing Hp quadruple therapy (group B: lansoprazole 30 mg qd, clarithromycin 250 mg bid, amoxycillin 500 mg tid for 10 d, plus killing H pylori capsule 6 capsules bid for 4 wk)
Trial: 15742421
Drug: New triple
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New triple therapy (group A: lansoprazole 30 mg qd, clarithromycin 250 mg bid, amoxycillin 500 mg tid for 10 d)
Trial: 15742421
Drug: Placebo (group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (group C: gastropine 3 tablets bid for 4 wk)
Trial: 15742421
Drug: Killing Hp
RxNorm normalized name: HP 502
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Killing Hp quadruple therapy (group B)
Trial: 15742421
Drug: New triple
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New triple therapy (group A)
Trial: 12023699
Drug: Nebulized magnesium
RxNorm normalized name: Hydra-Neb
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nebulized magnesium sulfate (384 mg in 6 mL of sterile water) plus albuterol (2.5 mg/3 mL)
Trial: 12023699
Drug: Albuterol (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Albuterol (2.5 mg/3 mL) alone
Trial: 10754431
Drug: isopolicosanol (3.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: isopolicosanol (3.6 mg/die for 7 days)
Trial: 10754431
Drug: octacosanol (3.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: octacosanol (3.6 mg/die for 7 days)
Trial: 8867776
Drug: Salt depletion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salt depletion (SD) with low sodium chloride dietary intake (< or = 60 mmol per day) and combined treatment with natriuretic and potassium sparing drugs
Trial: 8867776
Drug: Enalapril treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril treatment in the SD group
Trial: 8867776
Drug: LVP low-dose
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: LVP low-dose infusion during hypotonic polyuria
Trial: 6743784
Drug: Cimetidine formulation
RxNorm normalized name: Cimetidine
DrugBank: Cimetidine (DB00501)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cimetidine formulation A
Trial: 6743784
Drug: Cimetidine formulation
RxNorm normalized name: Cimetidine
DrugBank: Cimetidine (DB00501)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cimetidine formulation B
Trial: 30520208
Drug: Testosterone treatment
RxNorm normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Testosterone treatment combined with lifestyle intervention (Weight Watchers)
Trial: 26865390
Drug: BTH1677 at
RxNorm normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BTH1677 at 0.5, 1, 2, 4, or 6 mg/kg (Phase 1a)
Trial: 26865390
Drug: BTH1677 at
RxNorm normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BTH1677 at 1, 2, or 4 mg/kg (Phase 1b)
Trial: 24618964
Drug: Perioperative behavioral
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Perioperative behavioral therapy with pelvic floor muscle training (BPMT)
Trial: 8548891
Drug: Ticlopidine and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ticlopidine and aspirin therapy
Trial: 1824790
Drug: Zoladex (goserelin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zoladex (goserelin acetate implant)
Trial: 1824790
Drug: Serum testosterone
RxNorm normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Serum testosterone levels < 6.9 nmol/L
Trial: 30373539
Drug: Tighter glycaemic
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tighter glycaemic targets (fasting plasma glucose ≤5.0 mmol/L, 1 h postprandial ≤7.4 mmol/L, 2 h postprandial ≤6.7 mmol/L)
Trial: 30373539
Drug: Less tight
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Less tight glycaemic targets (fasting plasma glucose < 5.5 mmol/L; 1 h postprandial < 8.0 mmol/L; 2 h postprandial < 7.0 mmol/L)
Trial: 26438533
Drug: S-flurbiprofen plaster
RxNorm normalized name: Flurbiprofen
DrugBank: Flurbiprofen (DB00712)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: S-flurbiprofen plaster (SFPP) 20 mg applied for 12 hours
Trial: 26438533
Drug: S-flurbiprofen plaster
RxNorm normalized name: Flurbiprofen
DrugBank: Flurbiprofen (DB00712)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: S-flurbiprofen plaster (SFPP) 2-60 mg applied for 24 hours
Trial: 26438533
Drug: Commercially available
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Commercially available flurbiprofen (FP) gel-type patch
Trial: 17824582
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy of clindamycin 1%-benzoyl peroxide (BPO) 5% topical gel with tretinoin microsphere (RAM) gel 0.04%
Trial: 17824582
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy of clindamycin 1%-benzoyl peroxide (BPO) 5% topical gel with tretinoin microsphere (RAM) gel 0.1%
Trial: 17824582
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy of clindamycin 1%-benzoyl peroxide (BPO) 5% topical gel with adapalene (AP) gel 0.1%
Trial: 17824582
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy of clindamycin 1%-benzoyl peroxide (BPO) 5% topical gel
Trial: 17008436
Drug: Carbohydrate intake
RxNorm normalized name: pyrrolidone carboxylate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbohydrate intake before (approximately 150 g) and during exercise (1 g.kg body weight(‐1).h(‐1))
Trial: 27146827
Drug: Oral tablet
RxNorm normalized name: Oral Tablet
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral tablet